Your Health, We Care
Dacomitinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
from FDA，2020.12
LuciusVersionofDacomitinib:DosageandAdministration,Indications,PrecautionsIndicationsDacomitinib is ···【more】
Recommended：1172025-17-12
The first-line treatment for metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21L858R substitution mutation.【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：34
LuciusVersionofDacomitinib:DosageandAdministration,Indications,PrecautionsIndicationsDacomitinib is indicated for the first-line treatment of patients with metastatic non-small cel···【more】
Article source：Lucius LaosRelease date：2025-12-17Recommended：117
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
